181 related articles for article (PubMed ID: 9987141)
1. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons.
Minutello M; Senatore F; Cecchinelli G; Bianchi M; Andreani T; Podda A; Crovari P
Vaccine; 1999 Jan; 17(2):99-104. PubMed ID: 9987141
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly.
De Donato S; Granoff D; Minutello M; Lecchi G; Faccini M; Agnello M; Senatore F; Verweij P; Fritzell B; Podda A
Vaccine; 1999 Aug; 17(23-24):3094-101. PubMed ID: 10462245
[TBL] [Abstract][Full Text] [Related]
3. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine.
Podda A
Vaccine; 2001 Mar; 19(17-19):2673-80. PubMed ID: 11257408
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine and an MF59-adjuvanted influenza vaccine after concomitant vaccination in ⩾60-year-old adults.
Song JY; Cheong HJ; Hyun HJ; Seo YB; Lee J; Wie SH; Choi MJ; Choi WS; Noh JY; Yun JW; Yun JG; Kim WJ
Vaccine; 2017 Jan; 35(2):313-320. PubMed ID: 27919632
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults.
Song JY; Cheong HJ; Tsai TF; Chang HA; Choi MJ; Jeon JH; Kang SH; Jeong EJ; Noh JY; Kim WJ
Vaccine; 2015 Aug; 33(36):4647-52. PubMed ID: 25980426
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M
Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
[TBL] [Abstract][Full Text] [Related]
9. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
Vesikari T; Pellegrini M; Karvonen A; Groth N; Borkowski A; O'Hagan DT; Podda A
Pediatr Infect Dis J; 2009 Jul; 28(7):563-71. PubMed ID: 19561422
[TBL] [Abstract][Full Text] [Related]
10. A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.
Reisinger KS; Holmes SJ; Pedotti P; Arora AK; Lattanzi M
Hum Vaccin Immunother; 2014; 10(8):2395-407. PubMed ID: 25424947
[TBL] [Abstract][Full Text] [Related]
11. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
Nassim C; Christensen S; Henry D; Holmes S; Hohenboken M; Kanesa-Thasan N
Pediatr Infect Dis J; 2012 Apr; 31(4):e59-65. PubMed ID: 22418661
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.
Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
Pediatr Infect Dis J; 2014 Dec; 33(12):e320-9. PubMed ID: 24978857
[TBL] [Abstract][Full Text] [Related]
13. Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine.
Song JY; Cheong HJ; Noh JY; Seo YB; Choi WS; Cho GJ; Hwang TG; Kim WJ
J Med Virol; 2013 Sep; 85(9):1591-7. PubMed ID: 23852684
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children.
Solares AR; Aragon CG; Pivaral RU; Prado-Cohrs D; Sales-Carmona V; Pellegrini M; Groth N
J Infect Dev Ctries; 2014 Sep; 8(9):1160-8. PubMed ID: 25212080
[TBL] [Abstract][Full Text] [Related]
15. A phase 1, randomized, observer blind, antigen and adjuvant dosage finding clinical trial to evaluate the safety and immunogenicity of an adjuvanted, trivalent subunit influenza vaccine in adults ≥ 65 years of age.
Otten G; Matassa V; Ciarlet M; Leav B
Vaccine; 2020 Jan; 38(3):578-587. PubMed ID: 31679865
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects.
Squarcione S; Sgricia S; Biasio LR; Perinetti E
Vaccine; 2003 Mar; 21(11-12):1268-74. PubMed ID: 12559808
[TBL] [Abstract][Full Text] [Related]
17. [Study on the safety and immunogenicity of MF59-adjuvanted influenza subunit vaccine in Chinese elderly].
Li RC; Fang HH; Li YP; Liu YP; Nong Y; Huang GB
Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun; 29(6):548-51. PubMed ID: 19040034
[TBL] [Abstract][Full Text] [Related]
18. MF59-adjuvanted seasonal trivalent inactivated influenza vaccine: Safety and immunogenicity in young children at risk of influenza complications.
Patel SS; Bizjajeva S; Heijnen E; Oberye J
Int J Infect Dis; 2019 Aug; 85S():S18-S25. PubMed ID: 31051279
[TBL] [Abstract][Full Text] [Related]
19. Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study.
Della Cioppa G; Vesikari T; Sokal E; Lindert K; Nicolay U
Vaccine; 2011 Nov; 29(47):8696-704. PubMed ID: 21906647
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults.
Frey S; Poland G; Percell S; Podda A
Vaccine; 2003 Oct; 21(27-30):4234-7. PubMed ID: 14505903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
